WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia
Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) is a lymphoid malignancy caused by the oncogenic transformation of immature T-cell progenitors with poor outcomes. WP1130 has shown potent activity against a variety of cancer but whether WP1130 has anti-T-ALL activity is not clear. USP...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12935-019-0773-6 |
id |
doaj-f0726dd3fc934045a32ccf506e57829c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hao Luo Bo Jing Yu Xia Yugen Zhang Meng Hu Haiyan Cai Yin Tong Li Zhou Li Yang Junmei Yang Hu Lei Hanzhang Xu Chuanxu Liu Yingli Wu |
spellingShingle |
Hao Luo Bo Jing Yu Xia Yugen Zhang Meng Hu Haiyan Cai Yin Tong Li Zhou Li Yang Junmei Yang Hu Lei Hanzhang Xu Chuanxu Liu Yingli Wu WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia Cancer Cell International WP1130 USP24 dCas9-SAM T-cell acute lymphoblastic leukemia Mcl-1 |
author_facet |
Hao Luo Bo Jing Yu Xia Yugen Zhang Meng Hu Haiyan Cai Yin Tong Li Zhou Li Yang Junmei Yang Hu Lei Hanzhang Xu Chuanxu Liu Yingli Wu |
author_sort |
Hao Luo |
title |
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia |
title_short |
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia |
title_full |
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia |
title_fullStr |
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia |
title_full_unstemmed |
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia |
title_sort |
wp1130 reveals usp24 as a novel target in t-cell acute lymphoblastic leukemia |
publisher |
BMC |
series |
Cancer Cell International |
issn |
1475-2867 |
publishDate |
2019-03-01 |
description |
Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) is a lymphoid malignancy caused by the oncogenic transformation of immature T-cell progenitors with poor outcomes. WP1130 has shown potent activity against a variety of cancer but whether WP1130 has anti-T-ALL activity is not clear. USP24, one target of WP1130, is one of the largest deubiquitinases and its detailed mechanism is poorly understood. The aim of this study was to explore whether WP1130 could suppress T-ALL and the role of USP24 in T-ALL. Methods Molecular docking and cellular thermal shift assay were performed to determine whether and how WP1130 directly interact with USP24. Mitochondrial transmembrane potential assay was measured via Rhodamine 123 staining. USP24 was reactivated using the deactivated CRISPR-associated protein 9 (dCas9)-synergistic activation mediator (SAM) system. The in vivo results were examined by tumor xenografts in NOD-SCID mice. All statistical analyses were performed with the SPSS software package. Results WP1130 treatment decreased the viability and induces apoptosis of T-ALL cells both in vitro and in vivo. Furthermore, we demonstrated that knockdown of USP24 but not USP9X could significantly induce growth inhibition and apoptosis of T-ALL cells. Oncomine database showed that USP24 expression was upregulated in T-ALL samples and Kaplan–Meier results indicated that the USP24 was negatively but USP9X was positively associated with survival in T-ALL patients. Additionally, we proposed that WP1130 directly interacts with the activity site pocket of USP24 in T-ALL cells, which leads to the decrease of its substrates Mcl-1. Mechanistically, WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. Conclusions Altogether, using WP1130 as a chemical probe, we demonstrate that USP24 but not USP9X is a novel target in T-ALL cells. Moreover, we uncovered that WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. These results provide that USP24-Mcl-1 axis may represent a novel strategy in the treatment of T-ALL and WP1130 is a promising lead compound for developing anti-T-ALL drugs. |
topic |
WP1130 USP24 dCas9-SAM T-cell acute lymphoblastic leukemia Mcl-1 |
url |
http://link.springer.com/article/10.1186/s12935-019-0773-6 |
work_keys_str_mv |
AT haoluo wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT bojing wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT yuxia wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT yugenzhang wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT menghu wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT haiyancai wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT yintong wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT lizhou wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT liyang wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT junmeiyang wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT hulei wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT hanzhangxu wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT chuanxuliu wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia AT yingliwu wp1130revealsusp24asanoveltargetintcellacutelymphoblasticleukemia |
_version_ |
1724858193774903296 |
spelling |
doaj-f0726dd3fc934045a32ccf506e57829c2020-11-25T02:23:39ZengBMCCancer Cell International1475-28672019-03-0119111410.1186/s12935-019-0773-6WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemiaHao Luo0Bo Jing1Yu Xia2Yugen Zhang3Meng Hu4Haiyan Cai5Yin Tong6Li Zhou7Li Yang8Junmei Yang9Hu Lei10Hanzhang Xu11Chuanxu Liu12Yingli Wu13Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineDepartment of Hematology, Shanghai First People’s Hospital, Shanghai Jiao Tong University School of MedicineState Key Laboratory of Medical Genomics, Department of Hematology, Faculty of Medical Laboratory Science, Ruijin Hospital, Shanghai Jiaotong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineDepartment of Clinical Laboratory, Children’s Hospital Affiliated to Zhengzhou UniversityHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineDepartment of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineHongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of MedicineAbstract Background T-cell acute lymphoblastic leukemia (T-ALL) is a lymphoid malignancy caused by the oncogenic transformation of immature T-cell progenitors with poor outcomes. WP1130 has shown potent activity against a variety of cancer but whether WP1130 has anti-T-ALL activity is not clear. USP24, one target of WP1130, is one of the largest deubiquitinases and its detailed mechanism is poorly understood. The aim of this study was to explore whether WP1130 could suppress T-ALL and the role of USP24 in T-ALL. Methods Molecular docking and cellular thermal shift assay were performed to determine whether and how WP1130 directly interact with USP24. Mitochondrial transmembrane potential assay was measured via Rhodamine 123 staining. USP24 was reactivated using the deactivated CRISPR-associated protein 9 (dCas9)-synergistic activation mediator (SAM) system. The in vivo results were examined by tumor xenografts in NOD-SCID mice. All statistical analyses were performed with the SPSS software package. Results WP1130 treatment decreased the viability and induces apoptosis of T-ALL cells both in vitro and in vivo. Furthermore, we demonstrated that knockdown of USP24 but not USP9X could significantly induce growth inhibition and apoptosis of T-ALL cells. Oncomine database showed that USP24 expression was upregulated in T-ALL samples and Kaplan–Meier results indicated that the USP24 was negatively but USP9X was positively associated with survival in T-ALL patients. Additionally, we proposed that WP1130 directly interacts with the activity site pocket of USP24 in T-ALL cells, which leads to the decrease of its substrates Mcl-1. Mechanistically, WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. Conclusions Altogether, using WP1130 as a chemical probe, we demonstrate that USP24 but not USP9X is a novel target in T-ALL cells. Moreover, we uncovered that WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. These results provide that USP24-Mcl-1 axis may represent a novel strategy in the treatment of T-ALL and WP1130 is a promising lead compound for developing anti-T-ALL drugs.http://link.springer.com/article/10.1186/s12935-019-0773-6WP1130USP24dCas9-SAMT-cell acute lymphoblastic leukemiaMcl-1 |